IntegraGen announced that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial confirms the relationship between miR-31-3p expression and the efficacy of anti-EGFR treatment. IntegraGen has recently announced the CE-IVD Marking and European commercial launch of the company’s miRpredX 31-3p kit, a simple ready-to-use kit designed to quantify the expression of the miR-31-3p in formalin-fixed, paraffin-embedded (FFPE) tumor samples. Earlier this year IntegraGen also announced a licensing agreement with the CERBA laboratories for the development of a laboratory developed test which measures the expression of the miR-31-3p. miRpredX 31-3p Test: The miRpredX 31-3p test is the first positive theranostic test for patients with metastatic colorectal cancer (mCRC). The miRpredX 31-3p test predicts the potential clinical benefits associated with first-line anti-EGFR therapy compared to anti-VEGF therapy or when second or further lines of treatment with anti-EGFR therapy is beneficial versus chemotherapy alone for patients with RAS wild type (WT) mCRC. A recent study demonstrated that expression of the miR-31-3p is a predictive marker of both overall survival and response to treatment with anti-EGFR therapy1. The study also demonstrated that patients whose expression level is measured below the pre-defined threshold treated with FOLFIRI plus cetuximab have a one year longer median overall survival, a 40% reduction in mortality risk, and a better treatment response compared to patients treated with FOLFIRI plus bevacizumab.